Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.48 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.48 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.44 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL26699805 | 0.98 | CA2 (0.47) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL28581863 | 0.98 | CA2 (0.47) | CA2CA12CA9ERCC1ERCC4 | |
| Potassium Ion SCHEMBL4091648 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL8049927 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL31286502 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL8049928 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL10604295 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL11388483 | 0.96 | ERCC1 (0.46) | CA2CA12CA9ERCC1ERCC4 | |
| SCHEMBL1578383 | 0.81 | CA1 (0.45) | CA2CA12CA9ALDH1A1KDM4E | |
| SCHEMBL243229 | 0.80 | ERCC5 (0.48) | CA2CA12CA9ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118904163-A | Preparation method and device for preparing phenylglycine by using pipelining continuous flow | 海连化工科技(绍兴)有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-110183348-A | N- (3- nitro -4- alkoxybenzoyl) amino acids, preparation method and its usage | 中国医科大学 | 2019-08-30 | — | — | CN | claimed |
| US-20260042790-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY | GALERA LABS LLC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4291587-B1 | PHOTOPOLYMERIZABLE HOE COMPOSITION | XETOS AG (DE) | 2025-11-12 | — | — | EP | disclosed |
| US-12416860-B2 | Photoresist film and application thereof | CHANG CHUN PLASTICS CO., LTD. (TW) | 2025-09-16 | — | — | US | disclosed |
| US-20250277122-A1 | Photopolymerizable HOE Composition | XETOS AG (DE) | 2025-09-04 | — | — | US | disclosed |
| US-20250230181-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY | GALERA LABS, LLC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250224674-A1 | PHOTOSENSITIVE RESIN FILM AND APPLICATION THEREOF | CHANG CHUN PLASTICS CO., LTD. (TW) | 2025-07-10 | — | — | US | disclosed |
| CN-113416170-B | Pentaaza macrocyclic ring complexes with oral bioavailability | 加莱拉实验室有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| US-4772314-A | PHENYLGLYCINES, MONOMERIC | TEIJIN LIMITED (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0200794-A1 | Derivatives of ubiquinone, process for their preparation and pharmaceutical compositions containing them | MAGIS FARMACEUTICI S.p.A. (IT) | 1986-11-12 | — | — | EP | disclosed |
| EP-0194679-A2 | Plant growth promoter and method of plant growth promotion | TEIJIN LIMITED (JP) | 1986-09-17 | — | — | EP | disclosed |
| US-4520103-A | GENETIC TRANSFORMATION OF HOST CELLS | AMGEN (US) | 1985-05-28 | — | — | US | disclosed |
| EP-0109583-A2 | Microbial production of indigo | AMGEN INC. (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0010918-B1 | ANTIFREEZE AGENTS | Smiths Industries Public Limited Company (GB) | 1983-04-13 | — | — | EP | disclosed |
| EP-0048165-A1 | Bis-tetrazolemethyl substituted beta-lactam antibiotics, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
| US-4304774-A | Bis-tetrazolmethyl substituted β-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| EP-0010918-A1 | Antifreeze agents | Smiths Industries Public Limited Company (GB) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CA2 3928/4885CA12 2659/4885CA1 3239/4885 |
| US-20260042790-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY | SLC30A7, SLC39A14, AP1M1 | CA2 872/4885CA12 695/4885CA1 592/4885 |
| US-20250230181-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY | SLC39A14, SLCO4C1, ORC3 | CA2 1209/4885CA12 427/4885CA1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.